We are live on ! Find out more
VCIM

Velan Capital Investment Management Portfolio holdings

AUM $160M
1-Year Est. Return 517.12%
This Fund
S&P 500
This Quarter Est. Return
+117.44%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$172M
AUM Growth
+$65.9M
Cap. Flow
+$15.6M
Cap. Flow %
9.03%
Top 10 Hldgs %
70.98%
Holding
57
New
8
Increased
5
Reduced
5
Closed
11

Top Buys

Rank Stock Value
1
EVMN
Evommune Inc
EVMN
+$9.52M
2
MPLT
MapLight Therapeutics
MPLT
+$8.75M
3
ESPR
Esperion Therapeutics
ESPR
+$3.91M
4
TARA icon
Protara Therapeutics
TARA
+$3.87M
5
VRCA icon
Verrica Pharmaceuticals
VRCA
+$2.61M

Top Sells

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$5.96M
2
ZOOZ
ZOOZ Strategy Ltd
ZOOZ
+$4.28M
3
ALMS
Alumis Inc
ALMS
+$3.78M
4
QURE icon
uniQure
QURE
+$1.87M
5
TELA icon
TELA Bio
TELA
+$1.11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.72%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EDSA icon
26
Edesa Biotech
EDSA
$51.1M
$976K 0.57%
687,500
– –
TRVI icon
27
CALL
Trevi Therapeutics
TRVI
$2.53B
$482K 0.28%
+38,500
New +$445K
ARWR icon
28
Arrowhead Research
ARWR
$12.3B
$432K 0.25%
6,500
– –
VTYX
29
DELISTED
Ventyx Biosciences
VTYX
$361K 0.21%
40,000
– –
CTMX icon
30
CytomX Therapeutics
CTMX
$760M
$341K 0.2%
80,000
– –
PTGX icon
31
Protagonist Therapeutics
PTGX
$9.84B
$323K 0.19%
3,700
– –
NRIX icon
32
Nurix Therapeutics
NRIX
$2.76B
$304K 0.18%
16,000
– –
OVID icon
33
Ovid Therapeutics
OVID
$489M
$261K 0.15%
160,000
– –
GOSS icon
34
Gossamer Bio
GOSS
$86.8M
$217K 0.13%
70,000
– –
IMNM icon
35
Immunome
IMNM
$3.17B
$215K 0.12%
10,000
– –
DSGN icon
36
Design Therapeutics
DSGN
$917M
$188K 0.11%
20,000
– –
IMMX icon
37
Immix Biopharma
IMMX
$809M
$183K 0.11%
35,000
– –
CNTX icon
38
Context Therapeutics
CNTX
$43.2M
$147K 0.09%
100,000
– –
REPL icon
39
Replimune Group
REPL
$1.28B
$146K 0.08%
15,000
-5,000
-25% -$42.5K
LRMR icon
40
Larimar Therapeutics
LRMR
$454M
$126K 0.07%
33,000
– –
XLO icon
41
Xilio Therapeutics
XLO
$59.5M
$109K 0.06%
+12,143
New +$128K
CRBP icon
42
Corbus Pharmaceuticals
CRBP
$189M
$106K 0.06%
13,000
-48,000
-79% -$592K
PRQR icon
43
ProQR Therapeutics
PRQR
$262M
$90.9K 0.05%
45,000
– –
DTIL icon
44
Precision BioSciences
DTIL
$205M
$83.2K 0.05%
20,000
– –
PYXS icon
45
Pyxis Oncology
PYXS
$201M
$46K 0.03%
40,000
-15,000
-27% -$52.9K
PMVP icon
46
PMV Pharmaceuticals
PMVP
$67.2M
$43.8K 0.03%
35,000
– –
ACRS icon
47
Aclaris Therapeutics
ACRS
$860M
– –
-32,700
Closed -$62.1K
ALEC icon
48
Alector
ALEC
$240M
– –
-55,000
Closed -$163K
ELDN icon
49
Eledon Pharmaceuticals
ELDN
$291M
– –
-346,973
Closed -$899K
ERAS icon
50
Erasca
ERAS
$6.45B
– –
-65,000
Closed -$142K
1
2
3

Similar funds

BFAG
Blackston Financial Advisory Group The Villages, Florida $160M AUM 16.38% 1-Year Est. Return
SLG
Sanchez Levi Garrett $159M AUM
SMF
Sterling Manor Financial Saratoga Springs, New York $160M AUM 13.84% 1-Year Est. Return
LCA
Legend Capital Advisors New York $160M AUM
SGCM
Sanchez Gaunt Capital Management Reno, Nevada $160M AUM
RP
RIHO Partners Tucson, Arizona $159M AUM
PCC
Perry Creek Capital New York $160M AUM 3.05% 1-Year Est. Return
RCWM
Royal Capital Wealth Management Carmel, Indiana $161M AUM 18.42% 1-Year Est. Return

Velan Capital Investment Management's Q4 2025 Portfolio in Review

As of Q4 2025, Velan Capital Investment Management held 57 positions worth $172M, up 62% from $106M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Velan Capital Investment Management deployed $15.6M of net new capital in Q4 2025, opening 8 new positions and adding to 5 existing holdings. Its largest new stake was Evommune Inc: 506,754 shares worth $8.68M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Praxis Precision Medicines, an estimated $5.96M trimmed.

  • Velan Capital Investment Management's largest Q4 2025 buy was Evommune Inc: 506,754 shares worth $8.68M.
  • Velan Capital Investment Management added most to Protara Therapeutics in Q4 2025, an estimated $3.87M increase.
  • Velan Capital Investment Management's biggest Q4 2025 reduction was Praxis Precision Medicines, cutting an estimated $5.96M.
  • Velan Capital Investment Management fully exited ZOOZ Strategy Ltd in Q4 2025, selling an estimated $4.28M.
  • Velan Capital Investment Management's ten largest holdings make up 71% of its $172M portfolio in Q4 2025.
  • Velan Capital Investment Management opened 8 new positions and closed 11 in Q4 2025.
  • Velan Capital Investment Management's portfolio value rose 62% quarter-over-quarter to $172M.

Based on Velan Capital Investment Management's 13F filing for Q4 2025, filed 13 Feb 2026.